ANAB · AnaptysBio, Inc.

Current Thesis

The April 2026 spin-off rewrote this name. AnaptysBio is no longer a clinical-stage momentum biotech it shed its entire pipeline (rosnilimab, ANB033, ANB101) plus $100M cash into First Tracks Biotherapeutics (Nasdaq: TRAX, 1:1 distribution, record date 2026-04-06) and is now a pure-play royalty company on two assets: Jemperli (dostarlimab) via GSK and imsidolimab via Vanda. Everything that matters now collapses into one binary: the Tesaro/GSK Delaware Chancery trial, 2026-07-14 to 2026-07-17, which decides whether Anaptys recaptures Jemperli rights (reversion) and preserves its current 8–25% royalty rate. The 2026-04-24 ruling court dismissed Tesaro's anticipatory-breach claim and rejected its royalty-reduction request tilted the legal momentum toward Anaptys and popped the stock +12% on 2026-04-27. Spot $50.37 (2026-06-05) sits at the very floor of the $50–$140 analyst PT range. This is a litigation special-situation, not the accelerating narrative this book hunts.

Bull Case

• Royalty annuity on a growing PD-1. Jemperli/dostarlimab royalty is 8–25% of net sales, with composition-of-matter coverage to 2035 (US) / 2036 (EU) / 2037 (JP). It is a non-dilutive recurring stream tied to a GSK oncology franchise that keeps expanding indications.
• The reversion call option. If Anaptys wins the 2026-07-14/17 trial, it does not just keep the royalty it can recapture full Jemperli economics. The 2026-04-24 Delaware ruling already dismissed Tesaro's anticipatory-breach claim and rejected its royalty-cut request, putting the legal momentum on Anaptys's side into trial.
• Clean structure post-spin. By moving the cash-burning pipeline to First Tracks (2026-04-20 completion), ANAB removed clinical-trial dilution risk. What remains is a royalty book plus a legal call option no R&D cash drain.
• Second royalty trigger. Imsidolimab (partnered to Vanda) has an FDA action date of 2026-12-12 for generalized pustular psoriasis; Phase III data was published in NEJM (~2026-04-29). Approval adds a second stream at no further ANAB cost.
• Sell-side skews long. 10 buy / 0 sell, average PT $77.55 vs $50.37 spot (+54%), high $140 (Leevink Outperform → $85 on 2026-04-28, Piper Overweight → $93 on 2026-05-04).

Bear Case

• It is a coin flip with a date. The 2026-07-14/17 trial is the whole thesis. An adverse ruling vaporizes the reversion option and reopens Tesaro's royalty-cut path. Legal outcomes are not modellable; near the date this is a gamble, not an edge.
• The momentum leg is already spent. The stock round-tripped from the $73.30 52-week high back to $50 it gave back most of the post-ruling spike. There is no accelerating tape here; the next directional move is event-driven, weeks out.
• Sell-side was trimming, not chasing. Even into a court win, Barclays cut to $63 (2026-04-22), UBS cut to $60 (2026-04-21). Spot sits at the bottom of the range ($50 low estimate), not breaking out above it.
• Single counterparty risk. Royalty value rides entirely on GSK's execution of Jemperli; any deprioritization or sales softening shrinks the annuity directly.
• Wrong book. The clinical data catalysts that once made this a momentum name left with TRAX. The old "biotech-precision-therapeutics" peer-cluster framing (e.g. SGMT) no longer applies there is no theme cluster to confirm a momentum entry.

Setup & Price Structure

• Spot $50.37 (2026-06-05 close); after-hours $51.00. 52-week range $17.11–$73.30; market cap $1.47B (+~140% over the window). Beta 0.41 minimal market correlation; this trades on legal/royalty headlines, not the tape.
• Price action: gap-up +12% on 2026-04-27 off the favorable ruling → extended to the $73.30 high → faded to the low-$50s. That is a near-full retrace of the post-win spike now consolidating into the trial.
• $50 spot is wedged between a downside gap-fill near ~$40 (the April court-ruling gap / post-spin base) and the $73 highs. No clean accelerating breakout structure this is a pre-binary consolidation, and the resolution will be the verdict, not a moving-average reclaim.
• Low float-driven legal name: expect a violent ±20–40% gap on the July ruling rather than a trending leg.

Catalyst Calendar (next 30 days)

• 2026-07-14 → 2026-07-17 (~38 days out, just beyond the 30-day window): Tesaro/GSK Delaware Chancery trial. The binary Jemperli reversion + royalty-rate preservation. This dominates every other line item.
• ~early August 2026 (est.): Q2 2026 results first full quarter as a pure royalty company; the Jemperli royalty run-rate is the number to watch.
• 2026-12-12: Vanda imsidolimab FDA action date (GPP) far out, but a second royalty trigger.
• Note: no clinical-data catalysts remain at ANAB all pipeline readouts moved to TRAX. Nothing dated falls inside the next 30 days.

What Would Change Our Mind

• Adverse July 14–17 ruling (no reversion, Tesaro royalty-cut path reopened) → thesis dead, no second chance.
• Daily close below ~$40 fills the April court-ruling gap and breaks the post-spin base → special-situation premium unwinding ahead of the verdict.
• GSK guidance showing Jemperli/dostarlimab sales rolling over → the royalty annuity itself is impaired, independent of the trial.
• Reclaim and weekly close back above $73 on heavy volume pre-trial → market front-running a win; that would upgrade conviction and argue for a catalyst-archetype probe.
• A settlement announcement (either direction) collapses the binary into a known number and removes the call-option premium.

Correlation Notes

• Idiosyncratic. Beta 0.41 means little SPX/XBI sensitivity do not model this as biotech beta or a rate-sensitive name.
• Tightest links: GSK (owner/payer of the Jemperli royalty) and the spun-off TRAX (holds the pipeline + $100M cash). Vanda (VNDA) matters via imsidolimab.
• The prior biotech-precision peer cluster (SGMT and similar clinical-stage momentum names) is the wrong comp set now ANAB became a royalty/litigation vehicle whose outcome tracks the Delaware Chancery process, not the sector tape.